Medeon Biodesign (6499) — Financial Flexibility Index
Medeon Biodesign (6499) has a Financial Flexibility Index of -0.50x as of March 2026. Free cash flow of NT$-135.64 Million (operating CF NT$-140.26 Million minus capex NT$4.62 Million) represents -1% of total liabilities (NT$271.08 Million). Check Medeon Biodesign total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Medeon Biodesign Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Medeon Biodesign across 9 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Medeon Biodesign.
Annual Financial Flexibility Index for Medeon Biodesign (2017–2025)
Year-by-year free cash flow to debt coverage for Medeon Biodesign. Explore 6499 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.52x | NT$-612.26 Million | NT$-629.14 Million | NT$243.03 Million | ▼ -13.6% |
| 2024 | -2.22x | NT$-757.89 Million | NT$-832.66 Million | NT$341.84 Million | ▼ -19.1% |
| 2023 | -1.86x | NT$-699.26 Million | NT$-755.08 Million | NT$375.65 Million | ▼ -118.5% |
| 2022 | -0.85x | NT$-320.77 Million | NT$-461.34 Million | NT$376.48 Million | ▲ +47.4% |
| 2021 | -1.62x | NT$-285.06 Million | NT$-293.38 Million | NT$176.00 Million | ▼ -723.7% |
| 2020 | -0.20x | NT$-131.11 Million | NT$-151.27 Million | NT$666.83 Million | ▲ +72.7% |
| 2019 | -0.72x | NT$-193.09 Million | NT$-241.99 Million | NT$268.18 Million | ▼ -128.7% |
| 2018 | 2.51x | NT$373.19 Million | NT$322.05 Million | NT$148.89 Million | ▲ +262.9% |
| 2017 | -1.54x | NT$-162.21 Million | NT$-310.76 Million | NT$105.41 Million | — |